Liver disease accounts for approximately 2 million deaths per year worldwide, 1 million due
to complications of cirrhosis and 1 million due to viral hepatitis and hepatocellular …

Cholangiocarcinoma (CCA) is a heterogeneous group of malignancies with features of
biliary tract differentiation. CCA is the second most common primary liver tumour and the …

This guideline is the second European Crohn's and Colitis Organisation [ECCO] evidence-
based consensus on inflammatory bowel disease [IBD] and malignancy, and is an update …

Management of primary or secondary sclerosing cholangitis is challenging. These Clinical
Practice Guidelines have been developed to provide practical guidance on debated topics …

Acute inflammation is a response to an alteration induced by a pathogen or a physical or
chemical insult, which functions to eliminate the source of the damage and restore …

Primary sclerosing cholangitis (PSC) is a rare disorder characterised by multi-focal bile duct
strictures and progressive liver disease. Inflammatory bowel disease is usually present and …

This guideline has been approved by the American Association for the Study of Liver
Diseases and represents the position of the Association. These recommendations provide a …

Cholangiocarcinoma (CCA) is the second most common primary malignancy. Although it is
more common in Asia, its incidence in Europe and North America has significantly increased …

Background & Aims Primary sclerosing cholangitis (PSC) is an orphan hepatobiliary
disorder associated with inflammatory bowel disease (IBD). We aimed to estimate the risk of …

Cholangiocarcinoma (CC) is the second most common primary hepatic malignancy after
hepatocellular cancer. CC accounts for approximately 10%‐25% of all hepatobiliary …